WO2020141685A1 - Vésicules dérivées de lactobacillus paracasei et utilisation correspondante - Google Patents
Vésicules dérivées de lactobacillus paracasei et utilisation correspondante Download PDFInfo
- Publication number
- WO2020141685A1 WO2020141685A1 PCT/KR2019/010267 KR2019010267W WO2020141685A1 WO 2020141685 A1 WO2020141685 A1 WO 2020141685A1 KR 2019010267 W KR2019010267 W KR 2019010267W WO 2020141685 A1 WO2020141685 A1 WO 2020141685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- lactobacillus paracasei
- composition
- inflammatory
- vesicles
- Prior art date
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 103
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 40
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 208000004232 Enteritis Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 30
- 229920003045 dextran sodium sulfate Polymers 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 206010009887 colitis Diseases 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000013355 food flavoring agent Nutrition 0.000 description 10
- -1 inhalant Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 208000037976 chronic inflammation Diseases 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000000035 BCA protein assay Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Definitions
- the present invention relates to vesicles derived from Lactobacillus paracasei and uses thereof, and more particularly, to a composition for preventing or treating inflammatory diseases and cancer including vesicles derived from Lactobacillus paracasei as an active ingredient.
- the chronic disease is characterized by chronic inflammation accompanied by abnormal immune function, and various chronic inflammatory diseases, cancer, and the like, which are caused by this, have become a major problem for public health.
- Inflammation is a local or systemic defense mechanism against damage or infection of cells and tissues, mainly by the direct reaction of humoral mediators that make up the immune system or by stimulating the local or systemic effector system. It is triggered by a chain of biological reactions.
- the main inflammatory diseases include gastrointestinal diseases such as gastritis and inflammatory enteritis, oral diseases such as periodontitis, respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), rhinitis, atopic dermatitis, skin diseases such as psoriasis, degenerative arthritis, Arthritis such as rheumatoid arthritis, and cancer are known.
- compositions used to treat or prevent chronic inflammatory diseases are largely divided into steroidal and nonsteroidal compositions, many of which often have various side effects. Therefore, in recent years, there is a trend that interest in TNF- ⁇ inhibitors, which are pro-inflammatory cytokines known to be the main cause of chronic inflammatory diseases, is increasing.
- the present invention has been devised to solve the problems in the prior art as described above, and for the purpose of providing a composition for improving, preventing or treating inflammatory diseases and cancer, including vesicles derived from Lactobacillus paracasei as an active ingredient. do.
- the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases or cancer, comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a food composition for preventing or improving inflammatory disease or cancer, comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides an inhalant composition for the prevention or treatment of inflammatory diseases or cancer, including vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a cosmetic composition for preventing or improving inflammatory diseases, comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the inflammatory disease of the present invention is a disease mediated by TNF- ⁇ or IL-1 ⁇ , inflammatory enteritis (acute enteritis, chronic enteritis, etc.), gastritis, asthma, chronic obstructive pulmonary disease (COPD), rhinitis, atopic dermatitis, hair loss , Psoriasis, degenerative arthritis, and rheumatoid arthritis, but are not limited to diseases caused by an inflammatory reaction.
- inflammatory enteritis acute enteritis, chronic enteritis, etc.
- COPD chronic obstructive pulmonary disease
- rhinitis atopic dermatitis
- hair loss atopic dermatitis
- Psoriasis degenerative arthritis
- rheumatoid arthritis but are not limited to diseases caused by an inflammatory reaction.
- the cancer of the present invention includes, but is not limited to, colon cancer, stomach cancer, lung cancer, liver cancer, biliary tract cancer, pancreatic cancer, breast cancer, ovarian cancer, kidney cancer, bladder cancer, and prostate cancer.
- the vesicle preferably has an average diameter of 10 to 300 nm, but is not limited to vesicles that are secreted or separated naturally or artificially from Lactobacillus paracasei.
- the vesicles can be isolated from a culture medium by adding a culture medium of Lactobacillus paracasei or Lactobacillus paracasei, but is not limited thereto.
- the present invention provides a method of treating inflammatory disease or cancer comprising administering to a subject a composition comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a prophylactic and/or therapeutic use of an inflammatory disease or cancer of a composition comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a use for producing a drug used for inflammatory diseases and/or cancers of vesicles derived from Lactobacillus paracasei.
- Lactobacillus paracasei-derived vesicles according to the present invention can effectively suppress the expression of the pro-inflammatory cytokines TNF- ⁇ , IL-1 ⁇ , etc., which are known as factors of various chronic inflammatory diseases, various chronics with low side effects It is expected to be widely used as an improvement, prevention, or treatment of inflammatory diseases and cancer.
- FIGS. 1A and 1B are diagrams showing a result of analyzing vesicles derived from Lactobacillus paracasei according to an embodiment of the present invention.
- Figures 2a and 2b is a view showing the results of confirming the cytotoxic and inflammatory effects of Lactobacillus paracasei-derived vesicles according to an embodiment of the present invention.
- Figure 3 is a view showing the results of confirming the anti-inflammatory effect of Lactobacillus paracasei derived vesicles according to an embodiment of the present invention.
- 4A and 4B are diagrams showing the results of confirming the effect of inhibiting the LPS-induced inflammatory response of vesicles derived from Lactobacillus paracasei according to an embodiment of the present invention by qRT-PCR.
- Figures 5a and 5b is a view showing the results of confirming the effect of inhibiting LPS-induced inflammatory response of Lactobacillus paracasei derived vesicles according to an embodiment of the present invention by Western blotting.
- Figures 6a to 6e is a diagram showing the results of confirming the effect of inhibiting the inflammatory response of Lactobacillus paracasei-derived vesicles in DSS-induced colitis according to an embodiment of the present invention through histological analysis method.
- FIGS. 7A to 7D are diagrams showing the results of confirming the effect of inhibiting the inflammatory response of Lactobacillus paracasei-derived vesicles by qRT-PCR in DSS-induced colitis according to an embodiment of the present invention.
- FIGS. 8A and 8B are diagrams showing results of Western blotting confirming the effect of inhibiting the inflammatory response of Lactobacillus paracasei-derived vesicles in DSS-induced colitis according to an embodiment of the present invention.
- FIG. 9 is a view showing the results of measuring the size of cancer over time after orally administering vesicles derived from Lactobacillus paracasei in a cancer model made by transplanting cancer cells according to an embodiment of the present invention.
- the vesicles derived from Lactobacillus paracasei effectively suppressed the expression of various factors related to the inflammatory response, and showed a remarkable therapeutic effect in inflammatory diseases. Therefore, it is expected that the vesicles derived from Lactobacillus paracasei of the present invention can be used in various ways for improving, preventing, and treating various chronic inflammatory diseases and cancers.
- extracellular vesicle refers to a structure made of nano-sized membranes secreted by various bacteria, and in the present invention, a membrane naturally secreted from Lactobacillus paracasei or artificially produced membrane Collectively all structures.
- the vesicles are centrifuged, ultra-high-speed centrifugation, high-pressure treatment, extrusion, ultrasonic decomposition, cell lysis, homogenization, freeze-thaw, electroporation, mechanical decomposition, chemical treatment, filter to the culture medium containing Lactobacillus paracaseiforms Filtration, gel filtration chromatography, free-flow electrophoresis, and capillary electrophoresis.
- it may further include a process for removing impurities, concentration of the obtained vesicles, and the like.
- inflammation disease refers to a disease caused by an inflammatory reaction in the body, and representative examples include respiratory inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and rhinitis; Skin inflammatory diseases such as atopic dermatitis, psoriasis, acne, contact dermatitis, and hair loss; Digestive inflammatory diseases such as gastritis, gastrointestinal ulcer and inflammatory growthitis (acute enterocolitis, Crohn's disease, inflammatory bowel disease, Behcet's colitis, ulcerative colitis, bacterial colitis, etc.); vaginitis; Arthritis such as osteoarthritis and rheumatoid arthritis; And complications thereof.
- the inflammatory disease is used in a sense to include a metabolic disease related to the inflammatory response in addition to the general inflammatory disease, for example, diabetes, obesity, hepatitis, cirrhosis, and the like.
- prevention refers to all actions to suppress or delay the onset of inflammatory disease and cancer by administration of a food, cosmetic, inhalant, or drug composition according to the present invention.
- treatment refers to all actions in which symptoms of inflammatory disease and cancer are improved or beneficially changed by administration of a food, cosmetic, inhalant, or drug composition according to the present invention.
- improvement means any action that at least reduces the parameters associated with the condition being treated, eg, the severity of symptoms.
- ⁇ refers to a subject in need of treatment of a disease, and more specifically, a human or non-human primate, mouse, rat, dog, cat, Means mammals such as horses and cows.
- pharmaceutical composition may be characterized in the form of capsules, tablets, granules, injections, ointments, powders or beverages, the pharmaceutical composition characterized in that it targets humans Can.
- the pharmaceutical composition is not limited to these, but may be used in the form of oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injection solutions, respectively, according to a conventional method.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, coloring agents, flavoring agents, etc., when administered orally, in the case of injections, buffers, preservatives, and analgesic Agents, solubilizers, isotonic agents, stabilizers, etc. can be used in combination, and for topical administration, bases, excipients, lubricants, preservatives, etc. can be used.
- the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above.
- tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc. may be prepared, and in the case of injections, it may be prepared in unit dosage ampoules or multiple dosage forms.
- Others can be formulated as solutions, suspensions, tablets, capsules, and sustained release preparations.
- examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may be further included.
- the route of administration of the pharmaceutical composition according to the present invention is not limited to these, but oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical , Sublingual or rectal. Oral or parenteral administration is preferred.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, synovial, intrasternal, epidural, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical composition of the present invention may also be administered in the form of suppositories for rectal administration.
- the pharmaceutical composition of the present invention depends on a number of factors, including the activity, age, weight, general health, sex, diet, administration time, route of administration, release rate, drug combination and severity of the particular disease to be prevented or treated, of the specific compound used. It may vary, and the dosage of the pharmaceutical composition varies depending on the patient's condition, weight, disease severity, drug type, administration route, and duration, but can be appropriately selected by those skilled in the art, and 0.0001 to 50 mg per day /kg or 0.001 to 50 mg/kg. Administration may be administered once a day, or may be divided into several times. The above dosage does not limit the scope of the present invention in any way.
- the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions.
- the food composition may be used in various foods, for example, beverages, gums, teas, vitamin complexes, health supplements, etc., and may be used in the form of pills, powders, granules, needles, tablets, capsules, or beverages.
- the food composition includes a health functional food composition.
- the amount of the Lactobacillus paracasei-derived vesicles in food or beverages can generally be added at 0.01 to 15% by weight of the total food weight in the case of the food composition of the present invention, and in the case of a healthy beverage composition, based on 100 mL. It can be added at a rate of 0.02 to 10 g, preferably 0.3 to 1 g.
- a health functional food is a food that is manufactured and/or processed using ingredients or components having useful functions for the human body, and has characteristics in its components compared to general foods, thereby maintaining a more active health, or a purpose or expected effect Refers to food having.
- the food composition of the present invention may include food additives conventional in the art, for example, flavoring agents, flavoring agents, colorants, fillers, stabilizers, and the like.
- the food composition according to the present invention is an essential component, and there is no particular limitation on the components added in addition to the lactobacillus paracasei-derived vesicle, and may contain various flavoring agents or natural carbohydrates, etc., as additional components, like ordinary food.
- Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose, etc.; Polysaccharides such as dextrin, cyclodextrin; And sugars such as xylitol, sorbitol, and erythritol.
- natural flavoring agents tacumatine, stevia extract (e.g., rebaudioside A, glycyrrhizine, etc.)
- synthetic flavoring agents sacharin, aspartame, etc.
- the proportion of the natural carbohydrate is generally about 1 to 20 g per 100 mL of the composition of the present invention, preferably about 5 to 12 g.
- the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and It may contain salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. These ingredients can be used independently or in combination. The proportion of these additives is not so critical, but is generally selected from 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
- the cosmetic composition may contain 0.0005 to 50% by weight based on the total weight of the composition derived from the Lactobacillus paracasei vesicles.
- the composition of the present invention may contain one or more active ingredients exhibiting the same or similar function in addition to the Lactobacillus paracasei-derived vesicle.
- Cosmetics prepared with the cosmetic composition of the present invention can be prepared in the form of general emulsifying and solubilizing formulations.
- Cosmetics in emulsified formulations include nutrient makeup, cream, essence, etc., and solubilized formulations in cosmetics include softened makeup.
- a dermatologically acceptable medium or base it can be prepared in the form of an adjuvant that can be applied topically or systemically, which is commonly used in the field of dermatology.
- Suitable cosmetic formulations include, for example, solutions, gels, solid or dough anhydrous products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), nonionic It may be provided in the form of a vesicle dispersant, cream, skin, lotion, powder, ointment, spray or conceal stick. It can also be prepared in the form of a foam or aerosol composition further containing a compressed propellant.
- the cosmetic composition of the present invention may further include fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, and ionic forms Or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other commonly used in cosmetics. It may contain auxiliaries commonly used in cosmetic or dermatological fields such as ingredients. In addition, the above components may be introduced in an amount generally used in the field of dermatology.
- cosmetics and cleansing agents such as convergent makeup, softening makeup, nutrient makeup, various creams, essences, packs, foundations, cleansing agents, soaps, treatments, and cosmetics And so on.
- Specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, Contains formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, rust powder, and eye shadow.
- the active ingredient may be added to the inhaler as it is or used with other ingredients, and may be suitably used according to a conventional method.
- the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention or treatment).
- the present invention provides a method of treating inflammatory disease or cancer comprising administering to a subject a composition comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a prophylactic and/or therapeutic use of an inflammatory disease or cancer of a composition comprising vesicles derived from Lactobacillus paracasei as an active ingredient.
- the present invention provides a use for producing a drug used for inflammatory diseases or cancers of vesicles derived from Lactobacillus paracasei.
- administration refers to the introduction of the pharmaceutical composition of the present invention to a patient by any suitable method, and the route of administration of the composition of the present invention is through oral or parenteral various routes as long as it can reach the target tissue. Can be administered.
- “individual” means a subject in need of treatment of a disease, and more specifically, a human or non-human primate, a mouse, a mammal such as a dog, cat, horse, and cow. .
- Example 1 Isolation of vesicles derived from Lactobacillus paracasei
- Lactobacillus paracasei was inoculated in MRS (de Man-Rogosa and Sharpe) medium and absorbed at 37°C at 200 rpm (OD After incubation until 600 nm ) became 1.0 to 1.5, the cells were inoculated with LB (Luria Bertani) medium and cultured. Then, the culture solution containing the cells was collected and centrifuged at 10,000 g for 20 minutes at 4°C to obtain the supernatant from which the cells were removed.
- MRS de Man-Rogosa and Sharpe
- the obtained supernatant was filtered again using a 0.22 ⁇ m filter, and the filtered supernatant was used in a volume of 50 mL or less using a 100 kDa Pellicon 2 Cassette filter membrane (Merck Millipore) and a MasterFlex pump system (Cole-Parmer). Concentrated. The concentrated supernatant was filtered again using a 0.22 ⁇ m filter to separate vesicles derived from Lactobacillus paracasei. The amount of protein contained in the supernatant was measured using a Pierce BCA Protein Assay kit (Thermo Fisher Scientific).
- the average diameter of the vesicles isolated from the culture of Lactobacillus paracasei was 34.22 nm, and it was confirmed that the vesicles were normally separated.
- Lactobacillus paracasei cells were prepared. More specifically, the Lactobacillus paracasei cells cultured in the same manner as in Example 1 were heat treated at 70° C. for 1 hour, followed by centrifugation at 10,000 g for 20 minutes at 4° C. to inactivate by heat from which the supernatant was removed. Acquired cells were obtained. Then, the cells were resuspended using a phosphate buffered saline (PBS), and then the amount of protein was measured using a Pierce BCA Protein Assay kit (Thermo Fisher Scientific).
- PBS phosphate buffered saline
- Example 3 Confirmation of inflammation-inducing effect of Lactobacillus paracasei-derived vesicle
- Lactobacillus paracasei-derived vesicles were treated at a concentration of 0.1, 1, and 10 ⁇ g/mL in mouse macrophage cell line Raw 264.7. After the reaction, the degree of cell death and the amount of TNF- ⁇ secretion were measured. More specifically, after dispensing 5 ⁇ 10 Raw 264.7 cells into 48-well plates, treated with Lactobacillus paracasei-derived vesicles diluted with DMEM serum-free medium and cultured for 12 hours.
- ELISA was diluted with Capture antibody (Abcam) in a phosphate buffer solution and dispensed in 50 ⁇ L in 96-well plates, and reacted at 4° C. for 16 hours.
- phosphate buffer solution PBST
- RD phosphate buffer solution
- BSA bovine serum albumin
- Lactobacillus paracasei-derived vesicles do not affect cell survival
- the mouse macrophage cell line Raw 264.7 was pretreated and cultured at a concentration of 0.1, 1, 10, and 50 ⁇ g/mL in Lactobacillus paracasei-derived vesicles. , TNF- ⁇ secretion was measured. More specifically, after dispensing 5 ⁇ 10 Raw 264.7 cells into 48-well plates, the Lactobacillus paracasei-derived vesicles diluted with DMEM serum-free medium or the Lactobacillus paracasei cells prepared in the same manner as in Example 2 were prepared. Treated and incubated for 12 hours. Then, after treatment with a concentration of E. coli-derived vesicle 1 ⁇ g/mL, the cells were further cultured for 12 hours. And the secretion amount of TNF- ⁇ was measured in the same manner as in Example 3. The results are shown in FIG. 3.
- Example 5 Lactobacillus Paracasey Of the resulting vesicle LPS Confirm the effect of suppressing the induced inflammatory response
- LPS and/or Lactobacillus paracasei-derived vesicles were treated with colorectal cancer cell line HT29 cell line. More specifically, after culturing the HT29 cell line in DMEM medium containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin, the phosphate buffer solution was added. The cells were washed.
- FBS fetal bovine serum
- the vesicles derived from Lactobacillus paracasei were pre-treated at a concentration of 500 ng/mL and cultured for 12 hours.
- the cultured cells were treated with 1 ⁇ g/mL LPS and cultured again for 12 hours.
- qRT-PCR quantitative reverse transcriptase polymerase chain reaction
- qRT-PCR To perform qRT-PCR, after extracting total RNA from cells cultured according to the protocol provided by the manufacturer primarily using TRIZOL reagent (Invitrogen), and then measuring the amount of RNA using NanoDrop 2000 Spectrophotometer, M- CDNA was synthesized using MLV reverse transcriptase, and qRT-PCR was performed using the synthesized cDNA as a template. qRT-PCR was performed using Quant3 Studio Real-time PCR Systems (Applied Biosystems). For quantification, CyberGreen qPCR Mastermix kit was used according to the protocol provided by the manufacturer. The primer sequences used are described in Table 1, and the results are shown in FIGS. 4A and 4B.
- the inflammatory response is promoted by LPS and the pro-inflammatory cytokines of IL-1 ⁇ , IL-1 ⁇ , IL-2, IL-3, and TNF- ⁇
- LPS lactobacillus paracasei-derived vesicles
- the amount of protein was measured using a Pierce BCA Protein Assay kit (Thermo Fisher Scientific). Then, 40 ⁇ g of protein was subjected to SDS-PAGE (Bio-Rad Laboratories) using 8-12% SDS-polyacrylamide gel to separate the protein, and the isolated protein was protein with Hybond TM -ECL nitrocellulose membrane (Amersham Bioscience). Moved. And the membrane to which the protein was transferred was blocked using TBST with 5% skim milk at room temperature for 1 hour, then treated with a primary antibody diluted 1: 2,000 and reacted at 4°C for 16 hours.
- the secondary antibody bound to HRP diluted 1: 2,000 was treated and reacted at room temperature for 1 hour, and observed using an ECL detection system (Amersham).
- Antibodies to COX-2 and activated MMP9 were purchased from SantaCruz, antibodies to NF ⁇ and iNOS were purchased from BioLegend, and antibodies to ⁇ -actin, phospho-I ⁇ and I ⁇ were purchased from Cell Signaling Technology. The results are shown in FIGS. 5A and 5B.
- Example 6 Confirmation of the effect of inhibiting the inflammatory response of Lactobacillus paracasei-derived vesicles in DSS-induced colitis
- mice were treated with dextran sodium sulfate (DSS) to induce colitis. More specifically, after 7 weeks of age, male C57BL/6 mice were grown under normal conditions for a week and subjected to an adaptation period, 2 w/v% of DSS (MP Biomedicals, LLC) was mixed with drinking water and provided for 5 days. As a control (control), normal drinking water was provided for 5 days. Lactobacillus paracasei-derived vesicles were injected into mice using an oral tube (oral gavage) at 10 mg per mouse on the first day of DSS administration.
- DSS dextran sodium sulfate
- mice were anesthetized 13 days after the start of the experiment, and after extracting the colon, the length from the ileocecal junction to the rectum was measured and stored at -80°C for subsequent experiments.
- the disease activity index (DAI), weight, stool consistency, and blood stool level were recorded daily.
- disease activity was expressed as 1 when 100% or more, 2 when 80 to 90%, 3 when 80 to 90%, and 4 when less than 80% compared to body weight on day 0, and stool consistency is normal It was marked as 1 in the state, 2 in the slightly diluted state, 3 in the diluted state, and 4 in the same state as water.
- the stool level was 1 when normal, 2 when blood was on the stool, 3 when blood was observed on the anus, and 4 when blood was observed on both the stool and anus.
- FIGS. 6A to 6E The results are shown in FIGS. 6A to 6E.
- the length of the colon was shortened in the mice administered with DSS, but it was confirmed that the length of the colon was maintained in the experimental group in which the vesicles derived from Lactobacillus paracasei were administered together (FIGS. 6A and 6E ).
- the weight remained similar to that of the control group, and the disease activity was also reduced compared to the mice administered DSS (FIGS. 6B and 6D ).
- the experimental group in which the Lactobacillus paracasei-derived vesicles were administered together showed the same survival rate as the control group (FIG. 6C).
- Example 7 Confirmation of anticancer effect of Lactobacillus paracasei derived vesicles
- cancer was generated by injecting CT26 cells, mouse colon cancer cells, into mice. More specifically, male C57BL/6 mice, 6 weeks of age, were raised for 3 days under normal conditions, and after an adaptation period, 20 ⁇ g of Lactobacillus paracasei-derived vesicles were orally administered for 5 days. As a control (PBS, Control) PBS was orally administered for 5 days. On the 8th day from the start of the experiment, mice were injected subcutaneously with 1 x 10 6 CT26 cells, mouse colon cancer cells. Then, 20 ⁇ g of PBS or Lactobacillus paracasei-derived vesicles were orally administered for 3 days by administration for 5 days per week, once a day, and the size of the cancer was measured.
- the size of cancer increased exponentially in the control group administered only with PBS, but in the experimental group orally administered with vesicles derived from Lactobacillus paracasei, it was confirmed that the size of the cancer was about 50% smaller than the control group. Did. Through the above results, it was confirmed that the vesicles derived from Lactobacillus paracasei can effectively suppress the growth of cancer.
- the Lactobacillus paracasei-derived vesicle of the present invention effectively suppresses the expression of TNF- ⁇ , etc., which is known as a factor of various chronic inflammatory diseases, and not only exhibits anti-inflammatory effects, but also effectively grows cancer in cancer animal models. By inhibiting it, it was confirmed that it exhibits a prophylactic and/or therapeutic effect on various inflammatory diseases and cancers, and the vesicles derived from Lactobacillus paracasei of the present invention can be used for improvement, prevention, or treatment of various inflammatory diseases and cancers. It is expected to be possible.
- Lactobacillus paracasei-derived vesicles according to the present invention can effectively suppress the expression of the pro-inflammatory cytokines TNF- ⁇ , IL-1 ⁇ , etc., which are known as factors of various chronic inflammatory diseases, various chronics with low side effects It is expected to be widely used as an improvement, prevention, or treatment of inflammatory diseases and cancers, and thus there is a possibility of industrial use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne des vésicules dérivées de Lactobacillus paracasei et une utilisation correspondante, et, plus spécifiquement, une composition pour soulager, prévenir et traiter les maladies inflammatoires et le cancer, comprenant comme principe actif des vésicules dérivées de Lactobacillus paracasei capables d'inhiber efficacement diverses réponses inflammatoires.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI2021003752A MY195500A (en) | 2018-12-31 | 2019-08-13 | Vesicles Derived From Lactobacillus Paracasei And Use Of Same |
| CA3112889A CA3112889A1 (fr) | 2018-12-31 | 2019-08-13 | Vesicules extracellulaires isolees de la culture de lactobacillus paracasei et utilisation connexe |
| AU2019419281A AU2019419281B2 (en) | 2018-12-31 | 2019-08-13 | Vesicles derived from lactobacillus paracasei and use of same |
| CN201980087214.8A CN113260372A (zh) | 2018-12-31 | 2019-08-13 | 衍生自副干酪乳杆菌的囊泡及其用途 |
| BR112021003728-4A BR112021003728A2 (pt) | 2018-12-31 | 2019-08-13 | vesículas derivadas de lactobacillus paracasei e uso das mesmas |
| JP2021537084A JP2022514977A (ja) | 2018-12-31 | 2019-08-13 | ラクトバチルス・パラカゼイ由来の小胞及びその用途 |
| EP19907069.9A EP3912631A4 (fr) | 2018-12-31 | 2019-08-13 | Vésicules dérivées de lactobacillus paracasei et utilisation correspondante |
| SG11202104315XA SG11202104315XA (en) | 2018-12-31 | 2019-08-13 | Vesicles derived from lactobacillus paracasei and use of same |
| MX2021002412A MX2021002412A (es) | 2018-12-31 | 2019-08-13 | Vesiculas derivadas de lactobacillus paracasei y uso de las mismas. |
| US16/782,288 US10987386B2 (en) | 2018-12-31 | 2020-02-05 | Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei |
| PH12021550985A PH12021550985A1 (en) | 2018-12-31 | 2021-04-30 | Vesicles derived from lactobacillus paracasei and use of same |
| JP2023085584A JP2023109943A (ja) | 2018-12-31 | 2023-05-24 | ラクトバチルス・パラカゼイ由来の小胞及びその用途 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0174027 | 2018-12-31 | ||
| KR20180174027 | 2018-12-31 | ||
| KR10-2019-0048671 | 2019-04-25 | ||
| KR1020190048671A KR102098067B1 (ko) | 2018-12-31 | 2019-04-25 | 락토바실러스 파라카제이 유래 소포 및 이의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/782,288 Continuation US10987386B2 (en) | 2018-12-31 | 2020-02-05 | Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020141685A1 true WO2020141685A1 (fr) | 2020-07-09 |
Family
ID=70291099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2019/010267 WO2020141685A1 (fr) | 2018-12-31 | 2019-08-13 | Vésicules dérivées de lactobacillus paracasei et utilisation correspondante |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3912631A4 (fr) |
| JP (2) | JP2022514977A (fr) |
| KR (1) | KR102098067B1 (fr) |
| CN (1) | CN113260372A (fr) |
| AU (1) | AU2019419281B2 (fr) |
| BR (1) | BR112021003728A2 (fr) |
| CA (1) | CA3112889A1 (fr) |
| CL (1) | CL2021000415A1 (fr) |
| MX (1) | MX2021002412A (fr) |
| MY (1) | MY195500A (fr) |
| PH (1) | PH12021550985A1 (fr) |
| SG (1) | SG11202104315XA (fr) |
| WO (1) | WO2020141685A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114085792A (zh) * | 2021-11-17 | 2022-02-25 | 哈尔滨医科大学 | 一种用于防治结肠癌的副干酪乳杆菌及其应用 |
| CN114540227A (zh) * | 2022-02-21 | 2022-05-27 | 南京医科大学 | 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途 |
| CN116033836A (zh) * | 2020-07-14 | 2023-04-28 | 利斯库生物科学有限公司 | 包含意外片球菌或来源于其的细胞外囊泡作为有效成分的用于治疗脑部疾病的组合物 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102188020B1 (ko) | 2018-05-09 | 2020-12-07 | 주식회사 고바이오랩 | 락토바실러스 파라카제이 균주 및 그 용도 |
| KR102257130B1 (ko) * | 2020-06-16 | 2021-05-28 | 주식회사 엠디헬스케어 | 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물 |
| JP7385301B2 (ja) | 2020-06-16 | 2023-11-22 | エムディー ヘルスケア インコーポレイテッド | ラクトバチルス・パラカゼイ由来小胞を含む神経疾患又は精神疾患の予防又は治療用組成物 |
| KR102512516B1 (ko) | 2021-04-02 | 2023-03-22 | 한국과학기술연구원 | 옵투시폴린 (obtusifolin), 이의 유도체, 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 퇴행성관절염의 예방 또는 치료용 약제학적 조성물 |
| CN115305211A (zh) * | 2021-05-07 | 2022-11-08 | 葡萄王生技股份有限公司 | 益生菌胞外泌体及其用途 |
| EP4349354A1 (fr) * | 2021-06-03 | 2024-04-10 | MD Healthcare Inc. | Vésicules extracellulaires issues de bactéries lactobacilles et leur utilisation |
| KR20220169403A (ko) * | 2021-06-18 | 2022-12-27 | 한국생명공학연구원 | 락티카제이바실러스 속 또는 락토바실러스 속 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 |
| KR20230015688A (ko) * | 2021-07-23 | 2023-01-31 | (주) 에이투젠 | 신규한 락토바실러스 파라카제이 atg-e1 균주 또는 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
| KR20230136548A (ko) | 2022-03-18 | 2023-09-26 | 주식회사 엠디헬스케어 | 수율이 향상된 유산균 유래 세포외소포의 제조방법 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110052808A (ko) * | 2009-11-13 | 2011-05-19 | 충북대학교 산학협력단 | 균체외 다당을 생성하고 건강기능성 효과를 갖는 신규한 락토바실러스 파라카제이 |
| KR20110082481A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
| CN104894021A (zh) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
| KR20160008060A (ko) * | 2014-07-11 | 2016-01-21 | 한국식품연구원 | 락토바실러스 파라카제이(Lactobacillus paracasei)를 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환 또는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 |
| KR20170015958A (ko) * | 2015-03-11 | 2017-02-10 | 주식회사 엠디헬스케어 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
| KR20190048671A (ko) | 2017-10-31 | 2019-05-09 | 한국생산기술연구원 | 콤팩트하고 단순화한 사류 펌프의 디퓨저 설계 방법, 이에 의하여 설계된 디퓨저 및 이를 구비한 사류 펌프 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009848A2 (fr) * | 2009-07-20 | 2011-01-27 | Bracco Spa | Utilisation thérapeutique de probiotiques |
| JP5635690B2 (ja) * | 2010-07-01 | 2014-12-03 | ポステック アカデミー‐インダストリー ファウンデーション | 細菌由来マイクロベシクルを用いた癌治療及び癌診断方法 |
| KR101427363B1 (ko) * | 2011-11-23 | 2014-08-08 | 주식회사 쎌바이오텍 | 항암 약제학적 조성물 |
| US9808517B2 (en) * | 2012-04-06 | 2017-11-07 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
| KR101620815B1 (ko) | 2014-05-21 | 2016-05-13 | 한국생명공학연구원 | 해양 진균에서 분리한 페니실리놀라이드 a를 유효성분으로 함유하는 염증성 질환 예방 및 치료용 조성물 |
| KR102027029B1 (ko) * | 2017-05-25 | 2019-09-30 | (주)엠앤씨생명과학 | 유산균 함유 천연 리포좀, 그 제조방법 및 이를 포함하는 식품 또는 약학 조성물 |
-
2019
- 2019-04-25 KR KR1020190048671A patent/KR102098067B1/ko active IP Right Grant
- 2019-08-13 CA CA3112889A patent/CA3112889A1/fr active Pending
- 2019-08-13 MY MYPI2021003752A patent/MY195500A/en unknown
- 2019-08-13 AU AU2019419281A patent/AU2019419281B2/en active Active
- 2019-08-13 SG SG11202104315XA patent/SG11202104315XA/en unknown
- 2019-08-13 EP EP19907069.9A patent/EP3912631A4/fr active Pending
- 2019-08-13 BR BR112021003728-4A patent/BR112021003728A2/pt unknown
- 2019-08-13 WO PCT/KR2019/010267 patent/WO2020141685A1/fr unknown
- 2019-08-13 JP JP2021537084A patent/JP2022514977A/ja active Pending
- 2019-08-13 MX MX2021002412A patent/MX2021002412A/es unknown
- 2019-08-13 CN CN201980087214.8A patent/CN113260372A/zh active Pending
-
2021
- 2021-02-17 CL CL2021000415A patent/CL2021000415A1/es unknown
- 2021-04-30 PH PH12021550985A patent/PH12021550985A1/en unknown
-
2023
- 2023-05-24 JP JP2023085584A patent/JP2023109943A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110052808A (ko) * | 2009-11-13 | 2011-05-19 | 충북대학교 산학협력단 | 균체외 다당을 생성하고 건강기능성 효과를 갖는 신규한 락토바실러스 파라카제이 |
| KR20110082481A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
| KR20160008060A (ko) * | 2014-07-11 | 2016-01-21 | 한국식품연구원 | 락토바실러스 파라카제이(Lactobacillus paracasei)를 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환 또는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 |
| KR20170015958A (ko) * | 2015-03-11 | 2017-02-10 | 주식회사 엠디헬스케어 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
| CN104894021A (zh) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
| KR20190048671A (ko) | 2017-10-31 | 2019-05-09 | 한국생산기술연구원 | 콤팩트하고 단순화한 사류 펌프의 디퓨저 설계 방법, 이에 의하여 설계된 디퓨저 및 이를 구비한 사류 펌프 |
Non-Patent Citations (2)
| Title |
|---|
| CHONDROU, P.; KARAPETSAS, A.; KIOUSI, D.E.; TSELA, D.; TIPTIRI-KOURPETI, A.; ANESTOPOULOS, I.; KOTSIANIDIS, I.; BEZIRTZOGLOU, E.; : "Lactobacillus paracasei K5 displays adhesion, anti-proliferative activity and apoptotic effects in human colon cancer cells", BENEFICIAL MICROBES, vol. 9, no. 6, 7 December 2018 (2018-12-07), pages 975 - 983, XP009526175, ISSN: 1876-2883, DOI: 10.3920/BM2017.0183 * |
| DOMINGUEZ RUBIO, A. P. ET AL.: "Lactobacillus casei BL23 produces microvesicles carrying proteins that have been associated with its probiotic effect", FRONTIERS IN MICROBIOLOGY, vol. 8, 20 September 2017 (2017-09-20), pages 1 - 12, XP055684492 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116033836A (zh) * | 2020-07-14 | 2023-04-28 | 利斯库生物科学有限公司 | 包含意外片球菌或来源于其的细胞外囊泡作为有效成分的用于治疗脑部疾病的组合物 |
| CN114085792A (zh) * | 2021-11-17 | 2022-02-25 | 哈尔滨医科大学 | 一种用于防治结肠癌的副干酪乳杆菌及其应用 |
| CN114540227A (zh) * | 2022-02-21 | 2022-05-27 | 南京医科大学 | 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000415A1 (es) | 2021-09-20 |
| PH12021550985A1 (en) | 2021-11-08 |
| SG11202104315XA (en) | 2021-05-28 |
| JP2022514977A (ja) | 2022-02-16 |
| MX2021002412A (es) | 2021-04-28 |
| EP3912631A1 (fr) | 2021-11-24 |
| JP2023109943A (ja) | 2023-08-08 |
| AU2019419281B2 (en) | 2023-11-30 |
| MY195500A (en) | 2023-01-26 |
| AU2019419281A1 (en) | 2021-03-04 |
| CN113260372A (zh) | 2021-08-13 |
| BR112021003728A2 (pt) | 2021-05-25 |
| EP3912631A4 (fr) | 2022-11-30 |
| KR102098067B1 (ko) | 2020-04-07 |
| CA3112889A1 (fr) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020141685A1 (fr) | Vésicules dérivées de lactobacillus paracasei et utilisation correspondante | |
| US10987386B2 (en) | Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei | |
| WO2011152671A2 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires ou de maladies du système immunitaire, contenant de la ramaline | |
| WO2014193014A1 (fr) | Bactéries lactiques de taille nanométrique issues du kimchi | |
| WO2018030732A1 (fr) | Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation | |
| WO2021040371A1 (fr) | Composition anti-inflammatoire | |
| WO2018128408A1 (fr) | Composition pharmaceutique pour prévenir ou traiter des maladies allergiques telles que l'asthme ou l'atopie, comprenant de la baïcaléine en tant que substance active | |
| WO2012093755A1 (fr) | Composition comprenant des vésicules extracellulaires provenant d'une nourriture fermentée et utilisation de celle-ci | |
| WO2019004668A1 (fr) | Nanovésicule dérivée de bactéries du genre proteus et son utilisation | |
| WO2021230581A1 (fr) | Découverte d'une nouvelle akkermansia muciniphila ak32 et application correspondante pour la prévention ou le traitement d'une lésion intestinale | |
| WO2019156449A1 (fr) | Nanovésicules dérivées de bactéries du genre lactococcus et leur utilisation | |
| WO2012093754A1 (fr) | Composition comprenant des vésicules extracellulaires provenant de l'intérieur d'un corps de mammifère et utilisation de celle-ci | |
| WO2020166868A1 (fr) | Nanovésicules issues de bactéries du genre rothia et leur utilisation | |
| WO2019164230A1 (fr) | Nano-vésicules dérivées de bactéries de l'espèce cupriavidus et utilisation associée | |
| WO2018056676A1 (fr) | Composition pharmaceutique comprenant un extrait de maïs pourpre pour la prévention ou le traitement d'une maladie de la peau | |
| WO2020122448A1 (fr) | Nanovésicule dérivée de la bactérie weissella et son utilisation | |
| WO2023008615A1 (fr) | Composition pour inhiber la sécrétion de sébum comprenant de l'acide ellagique en tant que principe actif | |
| WO2022239916A1 (fr) | Nouvelle souche de bifidobacterium longum et son utilisation | |
| WO2023224426A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires comprenant en tant que principe actif des cellules souches mésenchymateuses avec une production accrue d'interleukine 10 par lactobacillus sakei cvl-001 | |
| WO2023090781A1 (fr) | Composition destinée à prévenir et améliorer la rosacée cutanée comprenant de l'acide isochlorogénique ou un sel de celui-ci en tant que principe actif | |
| WO2024053775A1 (fr) | Composition anti-inflammatoire comprenant des vésicules extracellulaires isolées de cellules souches mésenchymateuses dérivées des amygdales comme principe actif | |
| WO2023055051A1 (fr) | Peptide ayant une activité de prévention de la chute des cheveux ou de promotion de la pousse des cheveux, et son utilisation | |
| WO2023055055A1 (fr) | Peptide comportant une activité de prévention de la chute des cheveux ou favorisant la croissance des cheveux, et son utilisation | |
| WO2023055053A1 (fr) | Peptide ayant une activité de prévention de la chute des cheveux ou de favorisation de la pousse des cheveux et son utilisation | |
| WO2019070087A1 (fr) | Composition de blanchiment de la peau contenant une fusarisétine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19907069 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2019419281 Country of ref document: AU Date of ref document: 20190813 Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021003728 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 3112889 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 112021003728 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210226 |
|
| ENP | Entry into the national phase |
Ref document number: 2021537084 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2019907069 Country of ref document: EP Effective date: 20210802 |